Compare MKC & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MKC | HALO |
|---|---|---|
| Founded | 1889 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7B | 11.2B |
| IPO Year | 2007 | 2001 |
| Metric | MKC | HALO |
|---|---|---|
| Price | $55.19 | $108.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 11 |
| Target Price | $67.00 | ★ $78.64 |
| AVG Volume (30 Days) | ★ 2.6M | 2.3M |
| Earning Date | 03-31-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.80% | N/A |
| EPS Growth | ★ 0.34 | N/A |
| EPS | ★ 4.33 | 3.11 |
| Revenue | ★ $6,840,300,000.00 | $151,862,000.00 |
| Revenue This Year | $16.24 | $28.24 |
| Revenue Next Year | $3.71 | $12.56 |
| P/E Ratio | ★ $12.58 | $35.15 |
| Revenue Growth | ★ 1.73 | N/A |
| 52 Week Low | $44.82 | $61.23 |
| 52 Week High | $72.41 | $109.55 |
| Indicator | MKC | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 53.83 | 78.98 |
| Support Level | $49.91 | $67.12 |
| Resistance Level | $54.41 | N/A |
| Average True Range (ATR) | 1.28 | 3.46 |
| MACD | 0.00 | 0.45 |
| Stochastic Oscillator | 47.03 | 97.44 |
In its 135-plus-year history, McCormick has become the leading global manufacturer of spices, herbs, extracts, seasonings, and other flavorings. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and Cholula. This mix will be complemented by the pending addition of Unilever's food brands, primarily Knorr cooking aids and Hellmann's mayonnaise. After the deal close, the combined business is slated to generate 70% of sales from consumers and 30% from restaurants and other packaged food and beverage manufacturers. Around 40% of sales are slated to come from faster-growing emerging markets, with Europe (23%) and North America (36%) accounting for the remainder.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.